
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
APA Annual Meeting Page2011 Annual Meeting ScheduleScientific Program - Schedule of Meeting Sessions Meeting Registration Housing ReservationsAPA Staff Contact ListCourse Brochure [pdf]




